Loading...

David Binion MD

Gastroenterologist
UPMC Presbyterian Shadyside

Profile

Dr. David Binion is Co-Director of the Inflammatory Bowel Disease Center, and Director of Translational Inflammatory Bowel Disease Research, Director of the Nutrition Support Service and Medical Director of the Intestinal Rehabilitation and Transplant Center at the UPMC Presbyterian Hospital, where he also serves as Professor of Medicine, Clinical and Translational Science. He graduated with honors from Harvard University and obtained his medical training at the State University of New York at Buffalo School of Medicine prior to completing internal medicine residency at Rhode Island Hospital, Brown University Program in Medicine. Dr. Binion completed fellowships in Gastroenterology at University Hospitals of Cleveland, Mucosal Immunology at the Case Western Reserve University School of Medicine and Vascular Cell Biology at the Cleveland Clinic Foundation, all in Cleveland, Ohio. Dr. Binion has extensive clinical experience with IBD, having personally cared for over 4,000 patients with Crohn's disease and ulcerative colitis. His research efforts focus on defining the molecular and cellular mechanisms underlying human IBD as well as identifying high risk groups of patients and developing improved treatment strategies for these individuals. His research group helped to identify the devastating impact of the C. difficile epidemic on patients with IBD. He has published over 500 manuscripts and scientific abstracts centered on IBD, C. difficile and Precision Medicine. His laboratory has focused on the microvascular biology of the human intestine and Big Data Analytics to define Precision Medicine in patients with IBD. His research has been funded by the National Institutes of Health, the Crohn's and Colitis Foundation and the Department of Defense. Dr. Binion is a recipient of the Crohn's and Colitis Foundation of America’s Premier Physician Award and the Sherman Prize for Excellence in Crohn’s disease and Ulcerative Colitis Research in 2018.

Sessions

Back to the Search